Hongwei Fang

Hongwei Fang

Auto-generated profile, based on publicly available information

Hongwei Fang

Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LHLei Hou
Lei Hou
JZJinyuan Zhang
Jinyuan Zhang
YLYajing Liu
Yajing Liu
HFHongwei Fang
Hongwei Fang
LLLijun Liao
Lijun Liao
XWXiangrui Wang
Xiangrui Wang

13 July 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZSZhun Sun
Zhun Sun
ACAnning Chen
Anning Chen
HFHongwei Fang
Hongwei Fang
DSDonglin Sun
Donglin Sun
MHMeiying Huang
Meiying Huang
GQGuojun Qian
Guojun Qian
Inflammation resolution is critical for acute lung injury (ALI) recovery. Interleukin (IL)-10 is a potent anti-inflammatory factor. However, its role in ALI resolution remains unclear. We investigated the effects of IL-10 during the ALI resolution process in a murine lipopolysaccharide (LPS)-induced ALI model. Blockade of IL-10 signaling aggravates LPS-induced lung injury, as manifested by elevated pro-inflammatory factors production and increased neutrophils recruitment to the lung. Thereafter, we used IL-10 GFP reporter mice to discern the source cell of IL-10 during ALI. We found that IL-10 is predominantly generated by B cells during the ALI recovery process. Furthermore, we used IL-10-specific loss in B-cell mice to elucidate the effect of B-cell-derived IL-10 on the ALI resolution process. IL-10-specific loss in B cells leads to increased pro-inflammatory cytokine expression, persistent leukocyte infiltration, and prolonged alveolar barrier damage. Mechanistically, B cell-derived IL-10 inhibits the activation and recruitment of macrophages and downregulates the production of chemokine KC that recruits neutrophils to the lung. Moreover, we found that IL-10 deletion in B cells leads to alterations in the cGMP–PKG signaling pathway. In addition, an exogenous supply of IL-10 promotes recovery from LPS-induced ALI, and IL-10-secreting B cells are present in sepsis-related ARDS. This study highlights that B cell-derived IL-10 is critical for the resolution of LPS-induced ALI and may serve as a potential therapeutic target.

31 August 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
GQGuojun Qian
Guojun Qian
WJWenxia Jiang
Wenxia Jiang
DSDonglin Sun
Donglin Sun
ZSZhun Sun
Zhun Sun
ACAnning Chen
Anning Chen
XZXiaoren Zhang
Xiaoren Zhang

23 April 2024 in The Journal of Pain
Verified
Journal Article
Closed access
HFHongwei Fang
Hongwei Fang
QHQianhao Hou
Qianhao Hou
WZWei Zhang
Wei Zhang
ZSZehua Su
Zehua Su
JZJinyuan Zhang
Jinyuan Zhang
LLLijun Liao
Lijun Liao

24 June 2026 in Annals of Medicine
Verified
Journal Article
Open access
FLFeng Liu
Feng Liu
WSWang Shen
Wang Shen
DSDan Su
Dan Su
ZGZhaoming Guan
Zhaoming Guan
YZYi Zhang
Yi Zhang
LYLongqiu Yang
Longqiu Yang
Postoperative nausea and vomiting (PONV) is a common complication following thyroid surgery, often exacerbated by opioid use. Oliceridine, a novel G protein-biased μ-opioid receptor agonist, may reduce opioid-related adverse events. This study aimed to compare the impact of oliceridine versus sufentanil on the incidence and severity of PONV in patients undergoing thyroid surgery. In this prospective, double-blind, randomised controlled trial conducted between May 2025 and February 2026, 232 patients scheduled for thyroid surgery were randomly assigned to receive either oliceridine or sufentanil for intraoperative analgesia. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes included PONV severity, need for rescue anti-emetics, postoperative pain scores, recovery quality, and other adverse events. The incidence of PONV within 48 h postoperatively was significantly lower in the oliceridine group [13/107 (12%)] compared with the sufentanil group [31/110 (28%)] (OR = 0.35, 95% CI: 0.17-0.72, p = 0.006). Postoperative pain scores, rescue analgesia requirements, and Quality of Recovery-15 scores were comparable between the two groups (p > 0.05). Besides, exploratory unadjusted analyses revealed fewer rescue anti-emetics: O group 8/107 (8%) vs S group 25/110 (23%) (OR = 0.27, 95% CI: 0.12-0.64, p = 0.002); and less abdominal distension: O group 4/107 (4%) vs S group 19/110 (17%) (OR = 0.19, 95% CI: 0.06-0.57, p = 0.001). For young ASA I-II patients undergoing thyroid surgery, oliceridine yields adequate postoperative analgesia and lower PONV rates versus sufentanil. Additional trials involving high-intensity surgical procedures are needed to confirm consistent equivalence.